Rapport Therapeutics, Inc.
corporate_fare Company Profile
Rapport Therapeutics, Inc. (NASDAQ:RAPP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for RAPP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for RAPP spans 8-K, 4, 424B5, FWP.
Recent high-impact activity:
- Rapport Posts Q3 Loss of $40.2M, Pro Forma Cash of $815.4M and Runway Through 2029
- Director Healy Buys $20.4M of Rapport Stock at $21.00 Offering Price
- Rapport Closes ~$355M Raise: $175M Stock, $172.5M Convertible Notes, $30M PIPE
- Rapport Finalizes $21.00 Offering: 8.3M Shares Plus Warrants, ~$215.7M Net
- Rapport Prices $175M Stock, $150M Convertible Notes and $30M Private Placement
Financial Snapshot
Short Interest & Short Volume
1.79 days to coverFINRA reported short interest of 3,956,396 shares in RAPP as of the October 30, 2026 settlement, a 29.7% increase from the prior period — about 1.8 days to cover at its recent average daily volume. On November 20, 2026, 55.7% of RAPP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for RAPP, detected from its recent SEC filings · based on capital-structure filings through 2026-10-30.
Equity Offering Priced at $21.00 · Private Placement Adds ~$30M
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →